Tamtam Try Tamtam free
Universitätsspital Zürich logo

Universitätsspital Zürich account plan

Leading Swiss university hospital

At a glance

Universitätsspital Zürich is the Canton of Zurich's university hospital, with CHF 1,880 million operating income in 2025 and 10,857 employees.

Universitätsspital Zürich (USZ) is an independent public-law institution owned by the Canton of Zurich, providing inpatient and outpatient care, university teaching and research with the University of Zurich, and public-interest services. In FY2025 it treated 42,317 inpatients and recorded 882,000 outpatient visits. Operating income rose 7.7% to CHF 1,880 million and the group posted a consolidated profit of CHF 36 million, its first since 2019, with an EBITDA margin of 6.6%. It had 10,857 employees (8,033.7 FTE) at 31 December 2025. The group also includes ZüriPharm AG, the USZ Foundation and a 40% stake in laundry company ZWZ AG; CEO is Monika Jänicke and the hospital board (Spitalrat) is chaired by André Zemp.

Business units

Strategic priorities

USZ 2030 strategy
Four of six fields prioritised in 2025: highest quality, staff, digitalisation of the hospital and its processes, and self-financing, coordinated by a Transformation Office; it is now branded Spital der Zukunft.
Self-financing operations and new buildings
The aim is to finance operations and the new buildings from its own resources over the long term, supported by a results-improvement programme in 2026.
Digital hospital
An Epic clinical information system will replace 15 systems, with introduction starting in two years at the earliest; 166 small and seven large digital projects ran in 2025, including a real-time bed capacity dashboard, digital PROMs and automated rostering.
End-to-end patient pathways
A lung tumour pathway since 1 February 2025, breast and gynaecological tumour pathways in 2025, and eight more pathways planned by end 2026.
Quality, compliance and culture
A quality strategy adopted in June 2025 and a Compliance Roadmap with a CEO-chaired compliance committee, code of conduct, side-job register and a planned speak-up platform.
Staff retention
A personnel strategy with five initiatives; staff turnover fell to 12.0%, and residents' clinical working time is being cut to 45 hours.

Latest results

For H1 2026, the USZ reported a profit of CHF 15 million on revenue of CHF 890 million, with an EBITDA margin of 6.4%, against CHF 17 million and 6.8% in H1 2025 (unaudited figures for the USZ segment only). More than 22,000 inpatients were treated (+7%) and outpatient visits rose 5% to about 461,000. Management credits the higher patient numbers and strict cost and resource management. For 2026 the annual report expects the switch to TARDOC and outpatient flat rates to weigh on revenue.

Investments and deals

MITTE1|2 new building
A new campus building with 300 beds and 23 operating theatres, an emergency centre and modern radiology, with go-live targeted for summer 2031; TCHF 72,888 was invested in 2025, and the Kantonsrat approved a CHF 690 million commitment credit lent by the canton.
2025 capital spending
Total investments of TCHF 151,211, including TCHF 107,858 in real estate, TCHF 19,295 in medical equipment and IT spending on data platforms and the migration from SAP R3 to SAP4Hana.
Further building programme
Renovation of the listed WEST wing planned from 2028 and the laboratory centre NORD3 to follow MITTE1|2.
Radiopharmacy
New leased space in Schlieren with a cyclotron, with production for medical use starting in early 2026.

Challenges and risks

Outpatient tariffs
Outpatient tariffs are still not cost-covering, and TARDOC and outpatient flat rates from 1 January 2026 are expected to have a negative revenue effect.
Cardiac surgery investigation
The investigation commission UK 16/20 found glaring failures in 2016-2020 and reported 11 extraordinary deaths and 13 inappropriate uses of medical devices to the prosecutor; three Spitalrat members are stepping down.
Ageing, listed buildings
Many listed buildings carry a significant renovation backlog while large construction projects must be refinanced.
Delayed clinical system
The Epic clinical information system is delayed by a procurement appeal.
Cost pressure and skills shortages
The CEO cites skills shortages, rising personnel and infrastructure costs, administrative burden and insufficient tariffs; personnel expense of CHF 1,058 million is the largest cost line.

What leadership says

“Wir investieren gezielt in Qualität, Spitzenmedizin und unsere Mitarbeitenden”

Monika Jänicke, CEO · H1 2026 results press release, 11 August 2026 (we invest in a targeted way in quality, top medicine and our staff)

“Mit dem Neubau Campus Mitte 1|2 bauen wir das Spital der Zukunft.”

Monika Jänicke, CEO · Interview with Heime und Spitäler, 1 August 2025 (with the new Campus Mitte 1|2 we are building the hospital of the future)

“Was die Untersuchung aufgedeckt hat, ist ein Schock für uns alle.”

Monika Jänicke, CEO · Press conference on the cardiac surgery investigation, 5 May 2026 (what the investigation uncovered is a shock to all of us)

“Eine solide finanzielle Basis ist Voraussetzung dafür, dass das USZ seinen Auftrag in Versorgung, Forschung und Lehre langfristig erfüllen kann”

André Zemp, Chair of the Spitalrat · H1 2026 results press release, 11 August 2026

Where a supplier can help

Clinical system migration support
Replacing 15 systems with Epic, plus the SAP4Hana migration, creates demand for integration, data migration and change-management partners.
Hospital construction and equipment
MITTE1|2, the WEST wing renovation and NORD3 open doors for medical equipment, building technology and facility suppliers.
Workforce tools
Staff retention, automated rostering and reduced administration for residents, including dictation software, suit workforce management and clinical documentation vendors.
Cost and productivity programmes
Self-financing, a results-improvement programme and outpatient tariff pressure make cost-saving and process-optimisation offers relevant.
Compliance and quality tooling
The Compliance Roadmap, side-job register, speak-up platform and rebuilt clinical research audit programme fit governance, whistleblowing and quality management software.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Universitätsspital Zürich?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Universitätsspital Zürich

What is Universitätsspital Zürich?

USZ is the university hospital of the Canton of Zurich, an independent public-law institution providing patient care, teaching and research with the University of Zurich.

What is USZ's revenue?

Operating income was CHF 1,880 million in 2025, with a consolidated profit of CHF 36 million. H1 2026 revenue was CHF 890 million.

How many employees does USZ have?

USZ had 10,857 employees and 8,033.7 FTE at 31 December 2025.

What is USZ's strategy?

USZ 2030, now branded Spital der Zukunft, prioritises highest quality, staff, a digital hospital and self-financing, including end-to-end patient pathways and a new clinical information system.

Who leads USZ?

Monika Jänicke is CEO and chair of the Spitaldirektion, and André Zemp chairs the Spitalrat.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)